Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vacci... ( VLP Vaccine

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

Date:8/26/2008

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to

Address Gaps in Global Pandemic Preparedness

ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain. Avian influenza emerged in humans in Indonesia in 2005 and has caused 135 documented human cases, 81% of which have been fatal. (1)

In this study, the vaccine demonstrated strong neutralizing antibody titers across all three doses tested, exhibiting increasing antibody titers with the escalation of the dose. The study evaluated individuals who received two injections of 15 micrograms (mcg), 45 mcg, 90 mcg or placebo. Among those individuals in the 15 mcg arm, 72% had a neutralizing antibody titer of 1:20 or greater (four-fold rise from baseline) against the H5N1 A/Indonesia strain as did 73% of subjects in the 45 mcg arm and 94% of subjects in the 90 mcg arm. All subjects tested negative for neutralizing antibodies to the H5N1 A/Indonesia strain before vaccination and no responses were observed among individuals who received a placebo. Novavax's proprietary VLPs contain the surface proteins (hemagglutinin [HA] and neuraminidase [NA]) and matrix protein (M1) of the H5N1 A/Indonesia strain. Additional immunological responses induced by each of the components of the vaccine are being evaluated including responses against HA, NA and the M1 proteins.

Although t
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
2. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
3. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
4. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
5. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
6. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
7. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
8. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
9. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
10. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
11. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery

Post Your Comments:

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vacci...( VLP Vaccine - Coupled with Innovat...),Health